{"id":25652,"date":"2022-11-04T11:38:29","date_gmt":"2022-11-04T11:38:29","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/it\/?post_type=portfolio-products&p=25652"},"modified":"2022-12-13T09:35:42","modified_gmt":"2022-12-13T09:35:42","slug":"laprysta","status":"publish","type":"portfolio-products","link":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\/","title":{"rendered":"Laprysta"},"content":{"rendered":"

Laprysta\u00a0 \u00e8\u00a0 indicato\u00a0 come\u00a0 monoterapia\u00a0 nel\u00a0 trattamento\u00a0 delle\u00a0 crisi\u00a0 ad\u00a0 esordio\u00a0 parziale\u00a0 con\u00a0 o\u00a0 senza\u00a0 generalizzazione secondaria in adulti, adolescenti e bambini a partire dai 4 anni di et\u00e0 con epilessia.<\/p>\n

Laprysta \u00e8 indicato come terapia aggiuntiva:<\/p>\n

– nel trattamento delle crisi ad esordio parziale con o senza generalizzazione secondaria in adulti, adolescenti e bambini a partire dai 4 anni di et\u00e0 con epilessia;<\/p>\n

-nel trattamento delle crisi tonico-cloniche generalizzate primarie in adulti, adolescenti e bambini a partire dai 4 anni di et\u00e0 con epilessia generalizzata idiopatica.<\/p>\n

NRX\/162 dep in AIFA il 28\/11\/2022<\/p>\n

Laprysta \u00a0“50 \u00a0mg compresse rivestite con film” 56 compresse, \u00a0classe A\/RR, PP: 25,05 \u20ac<\/p>\n

Laprysta \u00a0“100 \u00a0mg compresse rivestite con film” 56 compresse, \u00a0classe A\/RR, PP: 50,10 \u20ac<\/p>\n

Laprysta \u00a0“150 \u00a0mg compresse rivestite con film” 56 compresse, \u00a0classe A\/RR, 75,17 \u20ac<\/p>\n

Laprysta \u00a0“200 \u00a0mg compresse rivestite con film” 56 compresse, \u00a0classe A\/RR, 100,23 \u20ac<\/p>\n","protected":false},"featured_media":0,"parent":0,"template":"","active-substance":[268],"product-category":[173],"therapeutic-area":[176],"class_list":["post-25652","portfolio-products","type-portfolio-products","status-publish","hentry","active-substance-lacosamide","product-category-linea-farmaceutica","therapeutic-area-epilessia"],"yoast_head":"\nLaprysta - Neuraxpharm Italia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Laprysta\" \/>\n<meta property=\"og:description\" content=\"Laprysta\u00a0 \u00e8\u00a0 indicato\u00a0 come\u00a0 monoterapia\u00a0 nel\u00a0 trattamento\u00a0 delle\u00a0 crisi\u00a0 ad\u00a0 esordio\u00a0 parziale\u00a0 con\u00a0 o\u00a0 senza\u00a0 generalizzazione secondaria in adulti, adolescenti e bambini a partire dai 4 anni di et\u00e0 con epilessia. Laprysta \u00e8 indicato come terapia aggiuntiva: – nel trattamento delle crisi ad esordio parziale con o senza generalizzazione secondaria in adulti, adolescenti e bambini […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Italia\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-13T09:35:42+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portfolio\\\/laprysta\\\/\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portfolio\\\/laprysta\\\/\",\"name\":\"Laprysta - Neuraxpharm Italia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\"},\"datePublished\":\"2022-11-04T11:38:29+00:00\",\"dateModified\":\"2022-12-13T09:35:42+00:00\",\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portfolio\\\/laprysta\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/\",\"name\":\"Neuraxpharm Italia\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Laprysta - Neuraxpharm Italia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta","og_locale":"it_IT","og_type":"article","og_title":"Laprysta","og_description":"Laprysta\u00a0 \u00e8\u00a0 indicato\u00a0 come\u00a0 monoterapia\u00a0 nel\u00a0 trattamento\u00a0 delle\u00a0 crisi\u00a0 ad\u00a0 esordio\u00a0 parziale\u00a0 con\u00a0 o\u00a0 senza\u00a0 generalizzazione secondaria in adulti, adolescenti e bambini a partire dai 4 anni di et\u00e0 con epilessia. Laprysta \u00e8 indicato come terapia aggiuntiva: – nel trattamento delle crisi ad esordio parziale con o senza generalizzazione secondaria in adulti, adolescenti e bambini […]","og_url":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\/","og_site_name":"Neuraxpharm Italia","article_modified_time":"2022-12-13T09:35:42+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\/","url":"https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\/","name":"Laprysta - Neuraxpharm Italia","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/it\/#website"},"datePublished":"2022-11-04T11:38:29+00:00","dateModified":"2022-12-13T09:35:42+00:00","inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/it\/portfolio\/laprysta\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/it\/#website","url":"https:\/\/www.neuraxpharm.com\/it\/","name":"Neuraxpharm Italia","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products\/25652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/types\/portfolio-products"}],"version-history":[{"count":29,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products\/25652\/revisions"}],"predecessor-version":[{"id":25827,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/portfolio-products\/25652\/revisions\/25827"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media?parent=25652"}],"wp:term":[{"taxonomy":"active-substance","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/active-substance?post=25652"},{"taxonomy":"product-category","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/product-category?post=25652"},{"taxonomy":"therapeutic-area","embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/therapeutic-area?post=25652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}